Aspira Biosystems Announces Acquisition by Nanomune

BURLINGAME, Calif. — July 20, 2004— Aspira Biosystems Inc., announced today that it has been acquired by Nanomune, a privately held company funded by Archangel BioVentures. This strategic merger will provide Nanomune with novel technology, developed by Aspira, for high specificity capture of targeted proteins. The resulting company will use the name and trademarks of Aspira. Financial terms of the deal were not disclosed.

"The acquisition of Aspira’s ProteinPrint™ technology expands our intellectual property position in nanotechnology," said Nathan Hamilton, Manager of Archangel BioVentures. “We are enthusiastic about the ability of the Nanomune team to build on Aspira’s achievements to date,” said Casey Lynch, the founding president of Aspira.

About Aspira Biosystems

Aspira Biosystems, Inc. is a privately held company headquartered in Burlingame, California developing breakthrough solutions for specific protein capture. Aspira’s patented ProteinPrint™ technology enables rapid generation of sequence-specific capture sites on polymeric beads, films and arrays. For more information on Aspira Biosystems, visit http://www.aspirabio.com.

About Archangel BioVentures

Archangel BioVentures, LLC is a closely held investment company that focuses on emerging Life Science and Healthcare businesses. Archangel BioVentures helps build value in portfolio companies by playing an active role in these businesses.